Tag: BTG
Boston Scientific closes acquisition of BTG
Boston Scientific has announced the completion of its acquisition of BTG, pursuant to the previously announced scheme of arrangement. BTG develops and commercialises products...
Thrombus dissolution with EKOS™ Acoustic Pulse Thrombolysis™ in everyday clinical practice
At the EKOS symposium at LINC 2019, Nils Kucher (Zurich, Switzerland), Houman Jalaie (Aachen, Germany) and Mert Dumantepe (Istanbul, Turkey) share their experiences in...
First successful implantation of the bioconvertible Sentry IVC filter
The world’s first bioconvertible IVC filter commercially offered in the USA (Sentry; from BTG) has been successfully implanted into the first patients outside of...
Sentry Bioconvertible IVC filter two-year results show zero tilt or migration
Two-year results for the SENTRY trial were presented at the Vascular Interventional Advances conference (VIVA; 5–8 November, Las Vegas, USA). The prospective, multicentre trial...
Boston Scientific announces recommended offer to acquire BTG
Boston Scientific has announced it has reached an agreement on the terms of a recommended offer to acquire BTG, a company headquartered in the...
ICEfx cryoablation system launches globally at CIRSE 2018
BTG has announced the global launch of its ICEfx cryoablation system. This is an evolution of the existing Visual ICE system, and according to...
BTG acquires Novate Medical
BTG has announced it has acquired Novate Medical, a medical device company focused on the prevention of pulmonary embolism in patients at high risk...
Northwestern University adopts radioembolization with TheraSphere as first-line treatment for HCC
BTG has announced that following positive results of its 15-year experience between 2003 and 2017 with TheraSphere, Northwestern University, Illinois, USA, has adopted Y-90...
Initial experience suggests cryoablation effective in treatment of benign soft tissue...
“There is little experience with the use of cryoablation in children. Our aim was to evaluate the feasibility of cryoablation for benign soft tissue...
First patient treated with vandetanib-eluting beads that are visible on CT...
Researchers from the University College London (UCL) Cancer Institute, London, UK, and BTG have begun the first clinical trial of an experimental treatment for...
BTG acquires Roxwood Medical
BTG today announces it has acquired Roxwood Medical, an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe...
SIO announces first grants in interventional oncology /immuno-oncology research programme
The Society of Interventional Oncology (SIO and BTG have announced their 2017 Interventional interventional oncology /immuno-oncology research grant recipients.
The interventional oncology /immuno-oncology research programme...
SIRT significantly better tolerated than sorafenib, but does not increase overall...
The 459-patient randomised controlled SARAH study shows that local treatments of advanced or inoperable hepatocellular carcinoma with selective internal radiation therapy (SIRT) did not...
BTG receives CE mark for DC Bead Lumi
BTG has received Class III CE mark certification for DC Bead Lumi, the first commercially available radiopaque drug-eluting bead (DEB) in the EU which...
Adding interventional oncology to immuno-oncology
Some research data suggest there could be a synergistic effect between immunotherapy and minimally invasive procedures. Tumour types that do not respond to checkpoint...
BTG and SIO to explore role of minimally invasive therapies in...
BTG has announced a collaboration with the Society of Interventional Oncology (SIO; a global organisation working to nurture and support interventional oncology worldwide) to...
BTG’s Varithena launched in Canada
Following Health Canada regulatory approval, BTG is to launch its polidocanol injectable foam (Varithena), a drug/device combination product used to treat varicose veins, in...
First pulmonary embolism patients in Hong Kong treated with the BTG’s...
The first Hong Kong-based patients diagnosed with pulmonary embolism have been treated using the newly available BTG EKOS system. The EKOS system includes an...
BTG and Mirada Medical announce CE mark certification for Simplicit90Y dosimetry...
BTG and Mirada Medical announced CE mark certification for the Simplicit90Y dosimetry software, designed to optimise the planning of Y-90 selective internal radiation therapy...
BTG launches βETA radiation safety programme at CIRSE 2016
BTG has launched the βETA Radiation Safety Programme, a new initiative designed to reduce the risk of radiation exposure when performing selective internal radiation...
